Otonomy To Challenge Multi-Dose Ear Drops With Otiprio Expansion Plans
Otonomy will file for expanded US approval of Otiprio for use in swimmer’s ear on the back of positive top-line Phase III data – the product has the potential to improve on current treatments in terms of dosing, and the news sent its share price up by more than 10%.
You may also be interested in...
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: Merck's Follow-On Insulin Edges Closer To Market; Braeburn Submits Another Buprenorphine Depot
The latest drug development news and highlights from our FDA Performance Tracker.
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are nine (plus a few extras) that have caught attention for one reason or another, e.g., for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.